C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation.
about
Renal transplantationCyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels.Review of the proliferation inhibitor everolimus.Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part ICyclosporin therapeutic drug monitoring--an established service revisited.Therapeutic monitoring of immunosuppressant drugs. Where are we?Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?The influence of circadian rhythms on the kinetics of drugs in humans.Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010.State of the art in therapeutic drug monitoring.Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy.Drugs to cure avian influenza infection--multiple ways to prevent cell deathImpact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.The transplanted child: New immunosuppressive agents and the need for pharmacokinetic monitoring.Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts.Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation.Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-β, tumour necrosis factor-α and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients.Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.Optimal sampling time-point for cyclosporin A concentration monitoring in heart transplant recipients
P2860
Q28769695-46567987-E07C-4ED3-B07C-069E9785DD7BQ30701607-1519236F-8423-4FEA-8849-84E356A0C671Q33345496-A2A5EFFD-9AEA-4FE2-A40B-7B8CC5FF0153Q34610933-DA561F62-E687-4F9A-B727-F9302E3EFAD7Q35759193-247E2E2D-C49E-423E-9BB2-F52029C115E2Q35970335-55EC1EEC-5CFD-424F-8D55-EFB916A1908FQ35980234-18ACE315-68A7-4BF2-8C62-4C81FFB9D314Q37076339-AB3C5F30-C68D-4990-81EB-88EE2CD7B28EQ37246076-B2987E4E-EEA7-4A8C-BF27-DA716DA2BFEFQ37699413-254B4F02-1588-4B81-9468-97B62F39AE30Q37738750-71658487-9682-4215-AA15-2F377C7BBBD6Q38148960-C35CDFB3-8E05-433E-A176-AC6B87D8B5ABQ42163344-FA8C8EA1-6DEE-437D-93C1-1AD8E0118055Q42597072-C343B65C-0FFE-4D4B-8F7F-8A06EC75903FQ42948459-4E45B3B4-A788-4B18-A051-932EDBB22691Q44133337-7784F6CE-F58E-493B-A39A-3F3484DC3170Q44405616-776F5E62-158F-4EF8-9493-B02B7FBF24A5Q46630204-4A9D118B-A154-4F76-BEEB-77F7FD138CBEQ46976291-17669D82-FDDB-46DA-ACAA-A7728BC88ADEQ47729633-D5CB17FD-FEA2-4733-90DC-DDB2A167CC00Q48228997-63B3F8E8-F0DD-42F3-B542-9DB44733281BQ58552338-BF29D6BB-2D96-4F74-978C-E51C495F2704
P2860
C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@ast
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@en
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@nl
type
label
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@ast
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@en
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@nl
prefLabel
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@ast
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@en
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@nl
P1433
P1476
C2 monitoring strategy for opt ...... n from the Neoral formulation.
@en
P2093
P304
P356
10.2165/00063030-200115050-00001
P577
2001-01-01T00:00:00Z
P6179
1031611196